Japan Tobacco : JT Transfers the Marketing Approvals of Six Anti-HIV Drugs in Japan to Gilead Sciences K.K.
September 02, 2019 at 02:57 am EDT
Share
FOR IMMEDIATE RELEASE
Tokyo, September 2, 2019
JT Transfers the Marketing Approvals of Six Anti-HIV Drugs in Japan
to Gilead Sciences K.K.
Japan Tobacco Inc. (JT) (TSE:2914) announces today that the transfer date of the marketing approvals of six anti-HIV drugs1 to Gilead Sciences K.K., the Japanese subsidiary of Gilead Sciences, Inc. (Gilead) is set for December 1, 2019. As announced in a press release2 on December 14, 2018, JT and Gilead terminated the license agreements under which Gilead granted an exclusive license for JT to develop and commercialize six anti-HIV drugs in Japan, effective on January 1, 2019.
After the transfer of the marketing approvals has completed, Gilead K.K. will be responsible for the distribution of those six drugs which Torii Pharmaceutical Co., Ltd (Torii) (TSE:4551) is currently responsible for, under the terms and conditions for a provisional measure.
The transfer will have an immaterial effect on the business performance of both JT and Torii's in this fiscal year.
###
Japan Tobacco Inc. is a leading international tobacco company with operations in more than 130 countries. With over 63,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its tobacco vapor products under the Ploom brand and various e-cigarette products under the Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit https://www.jt.com/.
Contact for Japan Tobacco Inc.:Masahito Shirasu, General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292E-mail:jt.media.relations@jt.com
Contact for Torii Pharmaceutical Co., Ltd.:Corporate Planning Department (Public Relations)
"Viread® Tablets 300mg" "Emtriva® Capsules 200mg" "Truvada® Combination Tablets" "Stribild® Combination Tablets*" "Genvoya® Combination Tablets*" "Descovy® Combination Tablets LT/HT" *Stribild® combination tablets and Genvoya® combination tablets contain the active ingredient elvitegravir, discovered by JT. JT granted the exclusive rights for Gilead to develop and commercialize elvitegravir in all countries of the world.
Japan Tobacco Inc. published this content on 02 September 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 September 2019 06:56:05 UTC
Japan Tobacco Inc. specializes in manufacturing and marketing of tobacco products. The group's products include primarily cigarettes, cigars, chewing and snuff tobaccos. Net sales break down by activity as follows:
- sale of tobacco products overseas (66%): 460 billion products sold in 2021, under the brands Winston, Camel, Silk Cut, Sobranie, Glamour, etc.;
- sale of tobacco products in Japan (24.1%): 67 billion products sold under the brands Cabin Prestige, Seven Stars, Pianissimo, Mild Seven, etc.;
- distribution of food products (6.3%);
- development of pharmaceutical products (3.5%): primarily for dyslipidemia, osteoporosis and Hepatitis C treatment;
- other (0.1%).
68.5% of net sales are abroad.
JAPAN TOBACCO, INC. 
